Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. (AKBA) Stock Overview
Explore Akebia Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
935M
P/E Ratio
-18.58
EPS (TTM)
$-0.21
ROE
1.67%
AKBA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Akebia Therapeutics, Inc. (AKBA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 42.72, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.11.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -18.58 and a market capitalization of 935M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.